BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19010835)

  • 1. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
    de Vos van Steenwijk PJ; Piersma SJ; Welters MJ; van der Hulst JM; Fleuren G; Hellebrekers BW; Kenter GG; van der Burg SH
    Clin Cancer Res; 2008 Nov; 14(22):7188-95. PubMed ID: 19010835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
    de Vos van Steenwijk PJ; Ramwadhdoebe TH; Löwik MJ; van der Minne CE; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Hellebrekers BW; Welters MJ; van Poelgeest MI; Melief CJ; Kenter GG; van der Burg SH
    Cancer Immunol Immunother; 2012 Sep; 61(9):1485-92. PubMed ID: 22684521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
    Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
    Front Immunol; 2021; 12():768144. PubMed ID: 35095843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
    de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
    Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
    Jiang B; Xue M
    Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
    van Poelgeest MI; Nijhuis ER; Kwappenberg KM; Hamming IE; Wouter Drijfhout J; Fleuren GJ; van der Zee AG; Melief CJ; Kenter GG; Nijman HW; Offringa R; van der Burg SH
    Int J Cancer; 2006 Feb; 118(3):675-83. PubMed ID: 16108057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
    Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
    Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
    J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization.
    Zhang L; Yang B; Zhang A; Zhou A; Yuan J; Wang Y; Sun L; Cao H; Wang J; Zheng W
    J Med Virol; 2016 Nov; 88(11):1982-8. PubMed ID: 27038009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
    Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
    J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
    Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
    Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
    J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses.
    Woo YL; van den Hende M; Sterling JC; Coleman N; Crawford RA; Kwappenberg KM; Stanley MA; van der Burg SH
    Int J Cancer; 2010 Jan; 126(1):133-41. PubMed ID: 19645010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
    Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
    Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variability and functional implication of HPV16 from cervical intraepithelial neoplasia in Shanghai women.
    Zhao J; Zhu J; Guo J; Zhu T; Zhong J; Liu M; Ruan Y; Liao S; Li F
    J Med Virol; 2020 Mar; 92(3):372-381. PubMed ID: 31670402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.
    Van Doorslaer K; Reimers LL; Studentsov YY; Einstein MH; Burk RD
    Gynecol Oncol; 2010 Feb; 116(2):208-12. PubMed ID: 19555999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
    van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
    Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology.
    Tsukui T; Hildesheim A; Schiffman MH; Lucci J; Contois D; Lawler P; Rush BB; Lorincz AT; Corrigan A; Burk RD; Qu W; Marshall MA; Mann D; Carrington M; Clerici M; Shearer GM; Carbone DP; Scott DR; Houghten RA; Berzofsky JA
    Cancer Res; 1996 Sep; 56(17):3967-74. PubMed ID: 8752165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.